Document Detail


The calcium channel antagonist, flunarizine, protects against ventricular fibrillation.
MedLine Citation:
PMID:  1601065     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Elevations in intracellular calcium during myocardial ischemia have been implicated in the development of lethal cardiac arrhythmias. The calcium antagonist, flunarizine, has been shown to suppress the accumulation of intracellular calcium and has been proposed to protect against triggered activity due to calcium overload. Using 13 mongrel dogs with healed myocardial infarctions, ventricular fibrillation (VF) was induced by a 2 min coronary occlusion during exercise. This exercise plus ischemia test consistently induced VF during control (C, vehicle) presentations. Pretreatment with flunarizine (2.5 mg/kg i.v.) completely suppressed VF in all the animals (P less than 0.001 Chi-squared). Flunarizine (F) elicited significant (P less than 0.01 ANOVA) reductions in left ventricular (LV) systolic pressure (C 143.2 +/- 12.0 F 92.3 +/- 10.5 mm Hg), LVdP/dt max (C 4256 +/- 251.9, F 1784 +/- 297.2 mm Hg/s) and heart rate (C 118.8 +/- 7.4, F 104.7 +/- 9.0 beats/min). Since heart rate can contribute significantly to the development of VF, the exercise plus ischemia test was repeated with heart rate held constant with ventricular pacing (n = 3, 230.0 +/- 10 beats/min). Flunarizine pretreatment still prevented VF under these conditions.
Authors:
G E Billman
Related Documents :
7490165 - Wavelet analysis of high-resolution ecgs in post-infarction patients: role of the basic...
21157305 - Update on management strategies for separation from cardiopulmonary bypass.
10700445 - Distribution of excitation frequencies on the epicardial and endocardial surfaces of fi...
11495505 - The use of echocardiographic colour kinetic wall motion to differentiate broad complex ...
12552545 - Compression of right ventricular out-flow due to localized hematoma after coronary perf...
16549275 - Altered electrical activity of fibrillation process following thrombolytic therapy in o...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  European journal of pharmacology     Volume:  212     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  1992 Mar 
Date Detail:
Created Date:  1992-07-13     Completed Date:  1992-07-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  231-5     Citation Subset:  IM    
Affiliation:
Department of Physiology, Ohio State University, Columbus 43210-1218.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Dogs
Flunarizine / therapeutic use*
Heart Rate / drug effects
Hemodynamics / drug effects
Ventricular Fibrillation / prevention & control*
Grant Support
ID/Acronym/Agency:
DA05917/DA/NIDA NIH HHS
Chemical
Reg. No./Substance:
52468-60-7/Flunarizine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Benzimidazolone derivatives act as 5-HT4 receptor ligands in rat oesophagus.
Next Document:  The selective 5-HT2 receptor antagonist amperozide attenuates 1-(2,5-dimethoxy-4-iodophenyl)-2-amino...